Clinical DevelopmentThe clinical hold on pociredir has been lifted, allowing FULC to proceed with its trials, potentially benefiting a larger patient population with its treatments.
Market ExpansionFULC plans to launch losmapimod in the US and is actively seeking a partner to bring the medication to markets outside the US, expanding its global footprint.
Product PipelineFULC is a biotech company developing small molecules to modify gene expression in rare diseases, with losmapimod in a pivotal Phase 3 trial and expectations for approval.